Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 483

Results For "US"

8889 News Found

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib
Clinical Trials | May 18, 2024

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months


Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
News | May 17, 2024

Cresset opens new new India HQ in Bengaluru to tap potential of APAC market

Cresset’s new India site will support the growing demands of Cresset’s APAC customer base


Glenmark launches next phase of ‘India First Heart First’ campaign
Healthcare | May 17, 2024

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases


Takeda appoints Annapurna Das as the General Manager, India Operations
People | May 17, 2024

Takeda appoints Annapurna Das as the General Manager, India Operations

Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines


Biocon posts Q4 FY24 PAT at Rs. 135 Cr
News | May 17, 2024

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%


Cipla invests additional Rs. 26 crore in Achira
News | May 16, 2024

Cipla invests additional Rs. 26 crore in Achira

Achira is engaged in development and commercialization of PoC medical test kits in India


Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer
Clinical Trials | May 16, 2024

Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer

225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer


Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab
Clinical Trials | May 14, 2024

Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab

Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria